Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Update Il y a 4 ans
Reference: NCT01348919

Woman and Man

Extract

The primary objective of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.


Inclusion criteria

  • Multiple myeloma

Links